Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Licensing In Brief

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Teva/Ivax merger creates pricing flexibility in generics: Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be" to forestall loss of business to competitors, according to Ivax Chairman Phillip Frost. Announced July 25, the deal creates the worldwide generic industry leader, based on combined 2004 sales of $6.1 bil. Post-merger, Teva says it will offer at least 300 products in the U.S. with a pipeline three times larger than that of its nearest competitor. The firm may reconsider its resistance to "authorized" generics following the merger: "We will definitely consider the new situation in the market and might reconsider our policy," Teva CEO Israel Makov said. A D.C. federal appeals court recently upheld FDA's refusal to block NDA holders from licensing or launching authorized generics. Novartis' Sandoz division (including Eon and Hexal) is the second largest generics firm with $5.1 bil. in 2004 sales; Novartis' Eon and Hexal purchases, announced in February and valued at about $8.7 bil. combined, closed in July and June, respectively...

You may also be interested in...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals


Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care

The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts